Cargando…

Detection of the XE subvariant of SARS-CoV-2: A perspective

Detalles Bibliográficos
Autores principales:	Rahimi, Farid, Talebi Bezmin Abadi, Amin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IJS Publishing Group Ltd. Published by Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047419/ https://www.ncbi.nlm.nih.gov/pubmed/35490952 http://dx.doi.org/10.1016/j.ijsu.2022.106642

Ejemplares similares

Implications of the SARS-CoV-2 subvariants BA.4 and BA.5
por: Rahimi, Farid, et al.
Publicado: (2022)

Emergence of the Omicron SARS-CoV-2 subvariants during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Hybrid SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2022)

‘The end’ – or is it? Emergence of SARS-CoV-2 EG.5 and BA.2.86 subvariants
por: Rahimi, Farid, et al.
Publicado: (2023)

Challenges of managing the asymptomatic carriers of SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

The Omicron subvariant BA.2: Birth of a new challenge during the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Highly contagious but less severe COVID-19 caused by new SARS-CoV-2 sublineages may abate the pandemic
por: Rahimi, Farid, et al.
Publicado: (2022)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Emergence of the Delta Plus variant of SARS-CoV-2 in Iran
por: Rahimi, Farid, et al.
Publicado: (2021)

Omicron: A highly transmissible SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

Case-finding: Fast, Available, and Efficient Font-line Diagnostics for SARS-CoV-2
por: Rahimi, Farid, et al.
Publicado: (2020)

Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012/01
por: Rahimi, Farid, et al.
Publicado: (2021)

The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2021)

A Commentary on “Omicron SARS-CoV-2 variant: Reasons of emergence and lessons learnt” (Int J Surg 2022;97:106198) Contact-tracing and global vaccine equity: Crucial responses to emergence of the Omicron SARS-CoV-2 variant
por: Rahimi, Farid, et al.
Publicado: (2022)

SARS-CoV-2 Lambda (C.37): An emerging variant of concern?
por: Darvishi, Mohammad, et al.
Publicado: (2021)

WHO prequalified tocilizumab and vaccine boosters against COVID-19
por: Rahimi, Farid, et al.
Publicado: (2022)

The Ukrainian refugee crisis and the COVID-19 pandemic in Europe
por: Rahimi, Farid, et al.
Publicado: (2022)

COVID-19 and science diplomacy
por: Rahimi, Farid, et al.
Publicado: (2022)

The 2022 monkeypox outbreak: Lessons from the 640 cases in 36 countries
por: Rahimi, Farid, et al.
Publicado: (2022)

Corrigendum to ‘Case-finding: Fast, Available, and Efficient Font-line Diagnostics for SARS-CoV-2’[Arch. Med. Res. 51(5) (2020) 453–454/ARCMED 2020 432]
por: Rahimi, Farid, et al.
Publicado: (2023)

Immediate countermeasures against the monkeypox outbreak
por: Rahimi, Farid, et al.
Publicado: (2022)

Severity of SARS-CoV-2 Omicron XBB subvariants in Singapore
por: Pung, Rachael, et al.
Publicado: (2023)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
por: Dijokaite-Guraliuc, Aiste, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Comment on “Gastric cancer and family history”
por: Abadi, Amin Talebi Bezmin
Publicado: (2017)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation
por: Wang, Qian, et al.
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains
por: Talebi Bezmin Abadi, A., et al.
Publicado: (2021)

Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains
por: Talebi Bezmin Abadi, A., et al.
Publicado: (2021)

Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants
por: Jian, Fanchong, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
por: Vatteroni, Maria Linda, et al.
Publicado: (2022)

Practical Strategies Against the Novel Coronavirus and COVID-19—the Imminent Global Threat
por: Rahimi, Farid, et al.
Publicado: (2020)

Comment on “circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer”
por: Rahimi, Farid, et al.
Publicado: (2019)

Tackling the COVID-19 Pandemic
por: Rahimi, Farid, et al.
Publicado: (2020)

Transparency and information sharing could help abate the COVID-19 pandemic
por: Rahimi, Farid, et al.
Publicado: (2020)

Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
por: Arora, Prerna, et al.
Publicado: (2022)

Cryo-EM structures of SARS-CoV-2 BA.2-derived subvariants spike in complex with ACE2 receptor
por: Li, Yaning, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gn002gudf93mqf6513esg09uh2